SCHEDULE 14A INFORMATION
Proxy Statement Pursuant To Section 14(a) Of
The Securities Exchange Act Of 1934
Filed by the Registrant [X]
Filed by a Party other than the Registrant [_]
Check the appropriate box:
[_] Preliminary Proxy Statement
[_] CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY
RULE 14A-6(E)(2))
[_] Definitive Proxy Statement
[X] Definitive Additional Materials
[_] Soliciting Material Pursuant to Section 240.14a-12
ICN Pharmaceuticals, Inc.
--------------------------------------------------------
(Name of Registrant as Specified in its Charter)
N/A
--------------------------------------------------------
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
[X] No fee required.
[_] Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.
(1) Title of each class of securities to which transaction applies:
-------------------------------------------------------------------
(2) Aggregate number of securities to which transaction applies:
-------------------------------------------------------------------
(4) Proposed maximum aggregate value of transaction:
-------------------------------------------------------------------
(5) Total fee paid:
-------------------------------------------------------------------
[_] Fee paid previously with preliminary materials.
[_] Check box if any part of the fee is offset as provided by Exchange Act
Rule 0-11(a)(2) and identify the filing for which the offsetting fee was
paid previously. Identify the previous filing by registration statement
number, or the Form or Schedule and the date of its filing.
(1) Amount Previously Paid:
-------------------------------------------------------------------
(2) Form, Schedule or Registration Statement No.:
-------------------------------------------------------------------
(3) Filing Party:
-------------------------------------------------------------------
(4) Date Filed:
-------------------------------------------------------------------
Following is the text of additional presentation materials delivered to
ICN Pharmaceuticals, Inc. stockholders on or about May 15, 2002:
Financial Position
SELECTED CONSOLIDATED BALANCE SHEET DATA
December 31, December 31, March 31, 2002
(US$mm) 2000 2001 Proforma(1)
--------------------------------------------------------------------------------------------------
Cash 155.6 327.6 411.0
Total Assets 1,477.1 1,754.4 1769.9
Senior Debt 496.9 191.2 ---
Convertible Debt - 525.0 525.0
Total Debt 510.8 740.7 542.7
Total Stockholders Equity 757.2 810.7 979.9
--------------------------------------------------------------------------------------------------
CREDIT STATISTICS
2000 2001 March 31, 2002
--------------------------------------------------------------------------------------------------
Total Debt/EBITDA 1.86x 2.80x 1.60x
EBITDA/Interest 4.56x 4.73x 9.60x(2)
Total Debt/Total Book Cap. 40% 48% 36%
(1) Assumes gain on Ribapharm IPO net of fees and retirement of Senior Notes
(2) Interest of Convertible Offering only
Inventories Q1 2001 - Q1 2002
-------------------------------------------------------------------------------
($000's)
[GRAPH OMITTED]
FY 2001 Q1 2001 Q2 2001 Q3 2001 Q4 2001 Q1 2002
Months
Sales Inv.
Actual 6.9 6.9 7.8 6.0 6.8
Net
Inventory
Actual 159,651 159,915 170,290 163,930 160,570
* Includes $3M due to cool touch acquisition
Actual Inventory 160 160 170 164 161
Accounts Receivable - Q1 2001 - Q1 2002
-------------------------------------------------------------------------------
[GRAPH OMITTED]
Trade Receivables
A/R Balance Unbilled Over 60
Month (1) and Other Balance Current 0-30 30-60 (2)
------------------------------------------------------------------------------
Q1 2001 161,703 14,135 147,568 117,653 17,314 6,839 5,762
Q2 2001 172,158 20,461 151,697 117,245 20,979 6,404 7,069
Q3 2001 167,922 15,427 152,495 117,543 18,117 7,491 9,344
Q4 2001 196,248 16,462 179,786 149,663 16,890 5,880 7,353
Q1 2002 187,547 15,730 171,817 137,265 16,667 8,607 9,278